Research Prospects and Strategies of CAR-Macrophage Based Cell Therapy in Solid Tumors

View Full Paper

Ask AI

Bookmark

The CAR-M cell therapy model shows 66.7% survival rate at day 28 and a 64.4% reduction in tumor volume.
In vitro results indicated a CD80 positivity rate of 76.4% and elevated IL-12 release to 312.7 pg/mL, outperforming controls.
The engineered macrophages address immunosuppressive environments, optimizing CAR design and transduction methods.
The findings suggest good potential for clinical translation of the CAR-M model in cancer treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

In vitro experiments showed CAR-M therapy improved IL-12 release and reduced tumor size, highlighting its potential for solid tumors.

Ziyang Gao (2025) studied this question.

View Full Paper

Ask AI

Bookmark